Funding for this research was provided by:
National Institute for Health Research (RP-PG-0407-10452)
Chief Scientist Office (CZB/A/680)
Guy's and St Thomas' Charity (SC039280)
European Research Council (669545)
National Institutes of Health (R01 DK10324)
Horizon 2020 (733206)
Medical Research Council (MR/L002477/1, MC_UU_1201/5)
Received: 2 January 2018
Accepted: 21 December 2018
First Online: 21 January 2019
Ethics approval and consent to participate
: This research complies with the Declaration of Helsinki. Approvals were obtained from the UK research ethics committee (UK integrated research application system, reference 09/H0802/5) and assent to participate was obtained from local Research and Development (R and D) departments for each participating centre. All women provided written informed consent prior to entering the study.This trial is registered with Current Controlled Trials, ISRCTN89971375 (ExternalRef removed) on July 23, 2008.
: SMN has received research support from Roche Diagnostics and Ferring Pharmaceuticals for research unrelated to the work presented here. DAL has received research support from Roche Diagnostics and Medtronic for research unrelated to the work presented here. All other authors declare they have no conflicts of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.